2. Search Result
Search Result
Results for "

lipid levels

" in MedChemExpress (MCE) Product Catalog:

120

Inhibitors & Agonists

1

Screening Libraries

6

Biochemical Assay Reagents

5

Peptides

1

MCE Kits

1

Inhibitory Antibodies

29

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-163654
    Ferroptosis-IN-8

    		Ferroptosis Cancer
    Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. Ferroptosis-IN-8 effectively reduces lipid ROS levels in cells. Ferroptosis-IN-8 act as an antioxidant by capturing lipid radicals, leading to a reduction in the accumulation of harmful lipid peroxides and, ultimately, inhibiting ferroptosis .
    Ferroptosis-IN-8
  • HY-108922
    Probucol disuccinate

    		Drug Derivative Metabolic Disease
    Probucol Disuccinate is a derivative of Probucol (HY-B0388), a lipid-regulating agent and can reduce LDL-cholesterol levels .
    Probucol disuccinate
  • HY-130587
    Sultosilic acid piperazine salt

    Piperazine sultosylate; A-585

    		 Others Metabolic Disease
    Sultosilic acid piperazine salt (Piperazine sultosylate; A-585) is a lipid-lowering agent. Sultosilic acid piperazine salt modifies the blood lipids levels, reduces platelet adhesiveness without promoting peroxisomal activity of hepatocytes or producing other adverse side-effects .
    Sultosilic acid piperazine salt
  • HY-156277
    SP4f

    		PPAR Metabolic Disease
    SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4f
  • HY-156276
    SP4e

    		PPAR Metabolic Disease
    SP4e is an activator of PPAR-γ, with the EC50 of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4e
  • HY-59273
    5-Nitroindole

    		Biochemical Assay Reagents ATP Synthase Metabolic Disease
    5-Nitroindole is a mutagenic nitroarene and universal base analog. 5-Nitroindole significantly reduces the cellular adenylate energy charge by decreasing ATP levels and increasing AMP levels. 5-Nitroindole inhibits lipid peroxidation .
    5-Nitroindole
  • HY-U00340
    PPAR agonist 1

    		PPAR Metabolic Disease
    PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
    PPAR agonist 1
  • HY-N1967
    Dihydrocurcumin

    		Fatty Acid Synthase (FASN) Metabolic Disease
    Dihydrocurcumin, a major metabolites of curcumin, reduces lipid accumulation and oxidative stress. Dihydrocurcumin regulates mRNA and protein expression levels of SREBP-1C, PNPLA3 and PPARα, increases protein expression levels of pAKT and PI3K, and reduced the levels of cellular NO and ROS via Nrf2 signaling pathways .
    Dihydrocurcumin
  • HY-B2078
    Eprazinone

    		Neurokinin Receptor Inflammation/Immunology
    Eprazinone can enhance lung function and arterial oxygen levels and can be used in the study of chronic bronchitis. Higher doses of eprazinone increased phospholipid levels and decreased neutral lipid content in bronchoalveolar lavage (BAL) fluid, but had no effect on protein and cell levels in BAL. Eprazinone dose-dependently reduced short-circuit current (Isc), primarily by reducing chloride secretion at lower concentrations and affecting sodium and chloride transport at higher doses. Eprazinone may exert its anti-inflammatory effects by regulating BAL lipid composition and airway ion transport .
    Eprazinone
  • HY-N7971
    2-Hydroxy-1-Methoxyaporphine

    		Endogenous Metabolite Cardiovascular Disease
    2-Hydroxy-1-Methoxyaporphine is an alkaloid that can be isolated from Nelumbo nucifera. 2-Hydroxy-1-Methoxyaporphine is the major active ingredient of the Chinese traditional medicine Jiang-Zhi-Ning .
    2-Hydroxy-1-Methoxyaporphine
  • HY-N2118
    Bilobetin
    2 Publications Verification

    		 PPAR PKA Akt p38 MAPK ERK Metabolic Disease
    Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
    Bilobetin
  • HY-176027
    CP-LC-1422

    		Liposome Others
    CP-LC-1422 is a homocysteine-derived ionizable amino lipid with high RNA delivery capability and can mediate high-level protein expression in vivo. CP-LC-1422 exhibits significant spleen targeting via intravenous injection in a lipid nanoparticle (LNP) formulation with no significant toxicity observed .
    CP-LC-1422
  • HY-101637
    Reglitazar

    JT 501

    		 PPAR Metabolic Disease
    Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .
    Reglitazar
  • HY-W587784
    Norbixin

    		PPAR Metabolic Disease
    Norbixin is a carotenoid that has been found in B. orellana.It binds to PPARγ in a cell-free assay (Ki = 1.15 μM) . Norbixin attenuates hyperglycemia, hyperinsulinemia, and insulin resistance, as well as decreases serum lipid levels and cardiac levels of thiobarbituric acid reactive substances (TBARS) and glutathione (GSH) in a rat model of cardio-metabolic syndrome .
    Norbixin
  • HY-N2118R
    Bilobetin (Standard)

    		Reference Standards PPAR PKA Akt p38 MAPK ERK Metabolic Disease
    Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
    Bilobetin (Standard)
  • HY-W015780
    1,4-Dimethoxybenzene

    		Endogenous Metabolite Metabolic Disease
    1,4-Dimethoxybenzene is an endogenous metabolite. 1,4-Dimethoxybenzene has an anti-anxiety effect, increasing atherogenic index (AI) levels in rabbits and inducing sedentary behavior. Sedentary behavior may increase blood cholesterol levels and disrupt blood lipids . 1,4-Dimethoxybenzene considers to be not clastogenic in the in vivo micronucleus test .
    1,4-Dimethoxybenzene
  • HY-W749927
    (Z)-9-Heptadecenoic Acid

    C17:1(9Z); Margaroleic acid

    		 Endogenous Metabolite Metabolic Disease
    cis-9-Heptadecenoic acid is a monounsaturated fatty acid that is a major constituent of ruminant fat and milk. The levels of cis-9-heptadecenoic acid in milk are negatively correlated with methane production in cows fed a high-lipid diet.
    (Z)-9-Heptadecenoic Acid
  • HY-173599
    NUV-244

    		Lipase Cancer
    NUV-244 is a PNPLA3 I148M degrader. NUV-244 reduces PNPLA3 I148M levels on lipid droplets via BFAR-mediated ubiquitin-proteasome degradation .
    NUV-244
  • HY-160552
    244cis

    		Liposome Others
    244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels .
    244cis
  • HY-129457
    FINO2
    5+ Cited Publications

    		 Ferroptosis Cancer
    FINO2 is a potent ferroptosis inducer. FINO2 inhibits GPX4 activity. FINO2 is a stable oxidant that oxidizes ferrous iron and stable at varying pH levels. FINO2 causes widespread lipid peroxidation .
    FINO2
  • HY-113168
    Butyrylcarnitine
    1 Publications Verification

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine
  • HY-155203
    Anticancer agent 154

    		Apoptosis Reactive Oxygen Species (ROS) Ferroptosis Cancer
    Anticancer agent 154 (Compound 8h) increases the levels of reactive oxygen species and leads to mitochondrial damage. Anticancer agent 154 induces cell apoptosis and DNA damage. Anticancer agent 154 also induces ferroptosis by reducing the GSH level and GPX4 expression and increasing the lipid peroxidation level. Anticancer agent 154 inhibits cancer cell (HT29, H1975, A549, and MCF-7) proliferation with IC50s of 1.0-1.9 μM .
    Anticancer agent 154
  • HY-165119
    1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PE

    PE(18:0/20:5); 18:0/20:5-PE

    		 Endogenous Metabolite Others
    1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PE (PE(18:0/20:5)) is a phospholipid identified in plasma lipid profile analysis, with similar lipid level changes in high-grade cervical intraepithelial neoplasia and cervical cancer compared with normal state and low-grade cervical intraepithelial neoplasia, and can be used to monitor cervical cancer progression.
    1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PE
  • HY-125953
    Ceramide (Egg)

    Ceramide (Egg, Chicken)

    		 Reactive Oxygen Species (ROS) Apoptosis Metabolic Disease
    Ceramide (Egg) is an intermediate of lipid. Ceramide (Egg) can be synthesized either by de novo biosynthesis or by salvage. Ceramide (Egg) level is associated with inflammation, ROS production and apoptosis. Ceramide (Egg) can be studied in research on non-alcoholic steatohepatitis (NASH) pathogenesis .
    Ceramide (Egg)
  • HY-168011
    GPX4-IN-14

    		Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) Cancer
    GPX4-IN-14 (compound 2c) is an inhibitor of GPX4, with free radical scavenging activity (maximum scavenging rate is 72.52%) and anti-tumor proliferation activity in vitro. GPX4-IN-14 inhibits GPX4 protein, increases lipid peroxide levels and intracellular Reactive Oxygen Species (ROS) levels, thereby inducing ferroptosis and exerting anti-tumor proliferation effects .
    GPX4-IN-14
  • HY-171904
    BCP-NC2-C12

    		Liposome Others
    BCP-NC2-C12 is an ionizable cationic lipid. BCP-NC2-C12 can be used to generate lipid nanoparticles (LNPs) for in vivo delivery of mRNA. BCP-NC2-C12 LNPs mediated an approximately 90% reduction in PCSK9 serum protein levels via CRISPR/Cas9 gene knockout .
    BCP-NC2-C12
  • HY-N13248
    Mulberry Leaf Extract

    		Glycosidase Metabolic Disease
    Mulberry Leaf Extract is a mulberry leaf extract, and its components include: 1-Deoxynojirimycin. Mulberry Leaf Extract can effectively alleviate the adverse effects of high-fat diet on blood lipids and renal function, regulate lipid metabolism abnormalities, and significantly inhibit the accumulation of glycosylated substances in glomeruli. Mulberry Leaf Extract can regulate the key signaling pathways of diabetic nephropathy, but does not directly affect blood glucose levels. .
    Mulberry Leaf Extract
  • HY-148626
    CVI-LM001

    		PCSK9 Metabolic Disease
    CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
    CVI-LM001
  • HY-117459
    E-3030 free acid

    		PPAR Metabolic Disease
    E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
    E-3030 free acid
  • HY-N0712
    Typhaneoside
    2 Publications Verification

    		 Autophagy Cardiovascular Disease Inflammation/Immunology
    Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function .
    Typhaneoside
  • HY-176212
    Ferroptosis-IN-20

    		Ferroptosis VDAC Reactive Oxygen Species (ROS) Inflammation/Immunology
    Ferroptosis-IN-20 (Compound 34a) is a Ferroptosis inhibitor (EC50: 24.2 nM) targeting voltage-dependent anion channel (VDAC). Ferroptosis-IN-20 inhibits VDAC oligomerization and lipid peroxidation. Ferroptosis-IN-20 reduces content of ROS, attenuates TFR1-mediated iron uptake, inhibits Fe 2+ level and restores glutathione (GSH) level. Ferroptosis-IN-20 alleviates Folic acid (HY-16637)-induced acute kidney injury (AKI) .
    Ferroptosis-IN-20
  • HY-152007S
    Butyrylcarnitine-d3 hydrochloride

    		Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine-d3 hydrochloride is deuterium labeled Butyrylcarnitine (HY-113168). Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine-d3 hydrochloride
  • HY-149120
    ASM-IN-1

    		Phospholipase Cardiovascular Disease Inflammation/Immunology
    ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
    ASM-IN-1
  • HY-W127497
    Methyl 12-Methyltetradecanoate

    		Biochemical Assay Reagents Others
    Methyl 12-Methyltetradecanoate is a methylated fatty acid methyl ester that has been found in vermicompost of cow dung, papaya leaves, and cuticle wax of K. africana. It is a volatile compound in lipid-reducing granule tea. The levels of methyl 12-methylmyristate were reduced in T. cruzi treated with nifurtimox compared to untreated controls.
    Methyl 12-Methyltetradecanoate
  • HY-153910
    AGPS-IN-1

    		Others Cancer
    AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
    AGPS-IN-1
  • HY-110150
    UNC3230
    Maximum Cited Publications
    7 Publications Verification

    		 PI4P5K Neurological Disease Inflammation/Immunology Cancer
    UNC3230 is a potent, selective and ATP-competitive PIP5K1C inhibitor with an IC50 of ~41 nM. UNC3230 also inhibits PIP4K2C and does not inhibit any of the other lipid kinases that regulate phosphoinositide levels. UNC3230 has antinociceptive and anticancer effects .
    UNC3230
  • HY-113168R
    Butyrylcarnitine (Standard)

    		Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine (Standard) is the analytical standard of Butyrylcarnitine (HY-113168). This product is intended for research and analytical applications. Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine (Standard)
  • HY-159483
    SelB-1

    		Topoisomerase Autophagy Glutathione Peroxidase Cancer
    SelB-1 serves as a dual inhibitor for Topoisomerase I/II. SelB-1 possesses anticancer activity and can be utilized in the research of prostate cancer and colon cancer. Furthermore, SelB-1 is also capable of inducing autophagy gene expression and lipid peroxidation, while simultaneously reducing the level of GSH .
    SelB-1
  • HY-135115
    Oleuropein Aglycone

    3,4-DHPEA-EA

    		 α-synuclein HDAC Adrenergic Receptor Inflammation/Immunology
    Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
    Oleuropein Aglycone
  • HY-W709961
    5-OAHSA

    1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .
    5-OAHSA
  • HY-B0757
    Vitamin E nicotinate

    		Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology
    Vitamin E nicotinate is the derivative of Vitamin E. Vitamin E nicotinate exhibits antioxidant activity and prevents lipid peroxidation. Vitamin E nicotinate upregulates levels of CD4+ T cells and IL-2, exhibits immunomodulatory activity. Vitamin E nicotinate exhibits antiplatelet and antihypertensive activities, that can be used in atherosclerosis and thrombosis ressearch .
    Vitamin E nicotinate
  • HY-109523
    Cerivastatin sodium
    2 Publications Verification

    		 HMG-CoA Reductase (HMGCR) Ferroptosis Cardiovascular Disease Cancer
    Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
    Cerivastatin sodium
  • HY-W749411
    Malondialdehyde tetrabutylammonium

    		Biochemical Assay Reagents Endogenous Metabolite
    Malondialdehyde tetrabutylammonium is a biomarker with antioxidant activity. Malondialdehyde tetrabutylammonium can be used as an indicator of lipid peroxidation to help assess oxidative stress levels. Malondialdehyde tetrabutylammonium is widely used in the food and cosmetics fields, mainly for monitoring and evaluating product stability and safety. Malondialdehyde tetrabutylammonium has an important role in indicating cell damage and is a potential biomarker for studying a variety of diseases.
    Malondialdehyde tetrabutylammonium
  • HY-158362A
    Monoglyceride lipase, Bacillus sp.

    		Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    Monoglyceride lipase, Bacillus sp., is a key enzyme involved in lipid metabolism. It catalyzes the hydrolysis of monoglycerides (particularly 2-AG, or 2-arachidonoylglycerol) into glycerol and free fatty acids. By regulating the levels of 2-AG, Monoglyceride lipase, Bacillus sp., can influence neural signaling, pain perception, inflammatory responses, and metabolic processes .
    Monoglyceride lipase, Bacillus sp.
  • HY-117912
    TRC210258

    		Endogenous Metabolite Cardiovascular Disease
    TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
    TRC210258
  • HY-N2468R
    Xylobiose (Standard)

    		TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose (Standard)
  • HY-N2468
    Xylobiose

    1,4-β-D-Xylobiose; 1,4-D-Xylobiose

    		 TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose
  • HY-139230
    OLHHA

    		Cannabinoid Receptor PPAR Metabolic Disease
    OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .
    OLHHA
  • HY-176557
    NCI677397

    		Deubiquitinase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Autophagy Cancer
    NCI677397 is a USP24 inhibitor. NCI677397 increases lipid ROS, activates cholesterol and fatty acid biosynthesis, degrades ABC transporters, GPX4 and DHFR through the autophagy pathway, decreases the level of P-gp and ultimately leads to ferroptosis in drug-resistant cancer cells. NCI677397 can be used for the study of lung caner and brain cancer .
    NCI677397
  • HY-129458
    Cerivastatin

    		HMG-CoA Reductase (HMGCR) Ferroptosis Cardiovascular Disease Cancer
    Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
    Cerivastatin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: